Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
about
Antimalarial drug combinations for treating uncomplicated malaria in pregnancyPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Genetic and epigenetic changes in host ABCB1 influences malaria susceptibility to Plasmodium falciparum.In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.Expanding the Antimalarial Drug Arsenal-Now, But How?Pancytopenia due to proguanil toxicity in a returning traveller with fever.Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.Can pharmacogenomics improve malaria drug policy?PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisininEmerging artemisinin resistance in the border areas of Thailand.Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.Pharmacogenomics of antimicrobial agents.Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites.Target validation: linking target and chemical properties to desired product profileDrug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa.Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers.Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity.Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase.Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Pharmacogenomic implications of the evolutionary history of infectious diseases in AfricaThe pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations.The pharmacogenetics of antimalaria artemisinin combination therapy.Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics.Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs.African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.New insight-guided approaches to detect, cure, prevent and eliminate malaria.A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.Expression of Organic Anion Transporting Polypeptide 1A2 in Red Blood Cells and Its Potential Impact on Antimalarial Therapy.Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquinePharmacogenomic strategies against microbial resistance: from bright to bleak to innovative.Does Plasmodium falciparum have an Achilles' heel?SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria.NAT2 sequence polymorphisms and acetylation profiles in Indians.LC-MS/MS method for the simultaneous quantification of artesunate and its metabolites dihydroartemisinin and dihydroartemisinin glucuronide in human plasma.Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine.Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates.Distribution of CYP2C Polymorphisms in an Amerindian Population of BrazilPopulation pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border
P2860
Q24188103-E8CCFDD4-6402-429E-B456-66E9FD52DBC5Q27012807-D9F275C5-2D0B-41CE-8256-C29ABBE45A4BQ33579831-3C6A2905-CD5A-4CB5-8923-703A68681447Q33712676-14167F93-E957-4948-9F5F-EB6480922941Q33916111-3A08E0EF-55F7-4D19-9A32-AE06035DCEB9Q33998735-D7E31522-A8CA-4D1F-9D56-B100D36FF720Q34015980-90923616-7043-403E-9C61-CA1E77AD604DQ34029396-3E7B3995-8E32-4798-AAD0-9137CD193D98Q34129977-7BF75E55-A84D-48E6-9019-C7E58FE60C0FQ34343530-E0F66BDC-E73C-40E1-A9FF-8347D58D3F18Q34491448-CF9EDD2B-F82C-4CB4-8FC8-B2A3117AF15EQ34977413-3EAF4423-EAB5-434E-85AA-A61159D904D4Q35225690-BB7F1D10-1FA6-4CB1-8C8A-1A45C3CB1CD6Q35237566-046BB4DC-18B5-4635-8C11-9CE5BCA36F11Q35602042-60B0EFB4-BB5C-4951-8481-1371CD6F355AQ35746024-69D58E3A-15FE-48D4-A70C-C81B0E04179DQ35746240-7CBFA909-8E85-4CB0-8840-C7EDD951E8BFQ35911482-D7CEC56F-C75E-4378-858E-0C9490E0817AQ36099352-3A38E738-0E48-440E-B6C0-BEC681D070F7Q36558437-2495E46A-2BC8-4FAA-B636-43A3C455411AQ37737731-FD259D1E-C9DA-4E1D-A4A1-28AFEB8A74D2Q37841602-1F43742A-4FFC-47BD-8AC2-BF0321E71455Q37928680-DDE3CD4A-0984-4FF5-8FE8-919DC3CDFD62Q37933394-33196903-41A9-4F61-B634-8C72FDF3A5D6Q38042679-26FDC6D1-F53C-4A39-9F70-4FF4E3399DB9Q38183664-97E830AB-9A21-44C8-A918-242C157D0301Q38260909-42EC413D-81F2-478F-AB0C-050918A4DA32Q38772466-EEF85222-FD34-4B18-95B0-FE80D485B498Q39509379-FD2C938A-AF10-4072-84D1-C51A49C94139Q39553303-533D7DC1-E57C-465C-8A30-66A608DAA72DQ39835147-E5A7EFDD-4FB5-41EF-8A19-B5E12E2C0009Q41688233-EF559E59-39D2-4546-8399-F0B77AB30ACFQ41911842-B44FA81B-61A9-4DF3-9E4E-5758722C8EDCQ42848863-E290D308-759E-4D0D-B112-D1AD6FCD5089Q46148230-C134BD0F-F39B-4591-9E9E-506DFA597EDCQ47864617-4CB2F730-77AE-45C6-9DD2-7DB1927BCBDFQ47998942-ECC44F54-9751-4DA5-86D9-152BE96FCBA5Q50048811-17971664-075B-4CE5-AFE5-5AC3AE3FC0FCQ57749415-3C09E7D2-E9BF-4235-B562-315A937968CDQ58768200-A73D844D-F929-4050-9DF9-13ABEF741797
P2860
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@ast
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@en
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@nl
type
label
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@ast
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@en
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@nl
prefLabel
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@ast
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@en
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@nl
P2093
P1476
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
@en
P2093
Christoph H Gleiter
Klaus Mörike
Matthias Schwab
Reinhold Kerb
Richard Fux
P304
P356
10.1016/S1473-3099(09)70320-2
P577
2009-12-01T00:00:00Z